Winston Salem, NC – Clinical ink, a global life science technology company, announces the promotion of John Pappadakis from EVP, Global Business Development to Chief Commercial Officer and Megan Petrylak from EVP, Clinical Operations to Chief Operating Officer. Jonathan Goldman MD, CEO of Clinical ink commented: “I am delighted to announce the promotion of two of our most seasoned and experienced executives.  With John Pappadakis as CCO, and Megan Petrylak as COO, Clinical ink has the ideal leadership team to drive us to the next phase of growth.  Our unwavering focus on quality and innovation make us the partner of choice for our biopharmaceutical partners and the patients they serve.”

John Pappadakis, Chief Commercial Officer

John has 34 years of experience in sales and marketing leadership roles within the pharma industry. His career includes commercial and R&D positions at Oracle and IMS Health, following positions of increasing seniority at Pfizer and Parke-Davis where he launched over 30 new molecular entities.

As Clinical ink’s EVP, Global Business Development, John devised an innovative go-to-market strategy centered around the addition of scientific and medical expertise, and the incorporation of new FDA requirements into the Clinical ink technology platform.  His vision inspired the creation of the company’s newest integrated cardiometabolic product, GlucoseReady.  Under his leadership, the company recruited a world-class commercial team and demonstrated record levels of key BD metrics.

As Chief Commercial Officer, John will further diversify Clinical ink’s customer base with the addition of new large, medium and small biopharmaceutical companies, whilst solidifying the company’s CRO relationships and other industry alliances.  His plans include the deepening of the therapeutic area focus on cardiometabolic, CNS, immunology and oncology, the introduction of an end-to-end decentralized/digital health platform centered around eCOA and EDCXtra, as well as new licensing-based business models.  Moving forward, John will be announcing novel and transformative AI-driven clinical trial innovations.

Megan Petrylak, Chief Operating Officer

Megan Petrylak has over 14 years of clinical trial experience in senior operational leadership roles. She has particularly focused on driving successful outcomes in phase 1-3 clinical trials for a wide range of global biopharmaceutical and CRO customers. Prior to her 6 year tenure at Clinical ink, Megan served as Director of Project Delivery at Worldwide Clinical Trials. Prior to that role, she headed Bioclinica’s centers for imaging and eClinical project management.

As EVP, Clinical Operations, Megan oversaw Clinical ink’s entire customer, site, and patient-facing operations function.  She augmented the team with deep expertise in data management and data quality, mandating a quality-first culture. This resulted in impressive increases in customer satisfaction, complemented by significant reductions in all study build and execution metrics and excellent quality outcomes.  In addition, Megan’s team successfully launched new products including GlucoseReady and EDCXtra and has developed a range of industry partnerships including TransPerfect for translations and eClinical Solutions for complex data solutions.  Her deep subject matter expertise in eCOA and data management has been recognized at numerous industry consortia and she has served as an expert speaker at meetings such as the Society of Clinical Data Management.

In her new role as Chief Operating Officer, Megan will oversee significant growth in Clinical ink’s revenue, broadening the customer base and expanding the range of integrated solutions. Her plans include upscaling the team to support the planned growth in revenue and margin profile, aided by automation of key operational and data processes. Megan will continue to prioritize quality to drive operational excellence and ensure exceptional delivery to clients.  

About Clinical ink

Clinical ink is the global life science company bringing data, technology, and patient-centric research together. Our deep therapeutic-area expertise, coupled with Direct Data Capture, eCOA, eConsent, telehealth, and digital biomarkers advancements (including use of Continuous Glucose Monitoring for detection of hypoglycemia), support the next generation of clinical trials and ultimately the clinical management of patients.

The post Clinical ink Announces the Promotion of John Pappadakis to Chief Commercial Officer and Megan Petrylak to Chief Operating Officer appeared first on Clinical ink.

Winston-Salem, NC – Clinical ink, a global life science technology company, announced the appointment of Dr. Nicholas Alp as Chief Medical Officer and EVP, Medical Science. In this role, Dr. Alp will lead the creation of innovative solutions and commercial strategies for clinical trial technology based on his experience as an interventional cardiologist and clinical trialist. His responsibilities will include the oversight of Clinical ink’s scientific advisory board, providing medical input to customer projects, and clinical focus to our range of products solutions.

Dr. Alp stated: “I am excited to join the leadership team at Clinical ink, where I look forward to helping my colleagues develop and deploy world-class data science solutions to enhance scientific insights and accelerate drug development for our Biopharma partners and for the benefit of patients”.

Dr. Alp has more than 30 years of clinical research experience and has spent the last 13 years in the life science industry. Prior to Clinical ink, he served as Senior Vice President of the Medical Department and head of Cardiometabolic Research at Medpace, a global clinical research organization.

Previously, Dr. Alp was Vice President and Global Head of Cardiovascular Drug Development at ICON. He simultaneously held appointments as a Consultant Interventional Cardiologist at the John Radcliffe Hospital, Oxford and a senior academic role in Cardiovascular Medicine at Oxford University.

Dr. Alp trained in medicine at London University and Oxford University, completed a PhD in Immunology at Cambridge University, with a further post-doctoral DM degree in Vascular Biology at Oxford University. He has also contributed to more than 70 peer-reviewed publications and books.

”I am delighted to welcome Nicholas to Clinical ink. He is a visionary clinician scientist with deep clinical research experience in cardiometabolic disease and other key therapeutic areas. Our customers and the patients they serve will benefit greatly from his ability to deploy clinically relevant eCOA, DDC, connected devices and patient engagement solutions” commented Clinical ink Chief Executive Officer Jonathan Goldman, MD.

About Clinical ink

Clinical ink is the global life science company bringing data, technology, and patient-centric research together. Our deep therapeutic-area expertise, coupled with Direct Data Capture, eCOA, eConsent, telehealth, and digital biomarkers advancements (including use of Continuous Glucose Monitoring for detection of hypoglycemia), support the next generation of clinical trials and ultimately the clinical management of patients.

The post Clinical ink Appoints Dr. Nicholas Alp, MD PhD as Chief Medical Officer appeared first on Clinical ink.

Winston-Salem, NC – Clinical ink, a global life science technology company, announced the appointment of Andrew Kraus as Chief Technology Officer. In this role, Kraus will lead the development of the company’s expanding technology portfolio to support clinical trials.

Kraus is an accomplished global healthcare executive with a 30-year track record of successful innovation in clinical trials leveraging his background in technology, strategy, operations, and finance. Prior to Clinical ink, Kraus served as Chief Operating Officer for World Care Clinical, a CRO providing centralized imaging and other services supporting clinical trials. He currently sits on the Board of Directors for Algorics, a specialized clinical data services company.

Mr. Kraus commented: “I am passionate about making a meaningful difference for patients by streamlining the clinical trials process. There is so much opportunity to simplify the capture of clinical data from patients. I am very excited to drive innovation as part of the Clinical ink team as we lead the industry in the development and deployment of integrated clinical trial technologies.” 

Previously, Kraus held executive roles at several companies leading clinical technology and operations. These included experience as Chief Operating Officer at Bioclinica (now part of Clario), SVP Service, Strategy and Operations at Signant, as well as Chief Operating Officer and Treasurer for the Cardiovascular Research Foundation.

Kraus has deep knowledge of the clinical trial space, having co-founded Beacon Bioscience as Chief Technology Officer and overseen its growth into a global imaging and clinical event adjudication provider prior to acquisition by ICON plc to become ICON Medical Imaging, where he managed all of ICON’s imaging and data technology businesses.

“I am delighted that Andrew has joined us as CTO,” said Clinical ink Chief Executive Officer Jonathan Goldman, MD. “He brings tremendous expertise in the use of technology to solve unmet needs in clinical trials and patient care to our organization. He is the right person to lead the growth of our patient-centered technology platform.”  

About Clinical ink

Clinical ink is the global life science company bringing data, technology, and patient-centric research together. Our deep therapeutic-area expertise, coupled with Direct Data Capture, eCOA, eConsent, telehealth, and digital biomarkers advancements (including use of Continuous Glucose Monitoring for detection of hypoglycemia), support the next generation of clinical trials and ultimately the clinical management of patients.

The post Clinical ink Appoints Andrew Kraus as Chief Technology Officer appeared first on Clinical ink.

The post Clinical ink CBO Jonathan Andrus Selected as DTRA Co-Leader Chosen to Head Decentralized Trials & Research Alliance Regulatory Gap Initiative appeared first on Clinical ink.

Horsham, Pa.; May 18, 2021 – Clinical Ink, a global clinical trial technology company, today announced the hiring of Janette Morgan as EVP, General Manager, EMEA. In this unique, hybrid role, Janette will manage the company’s dramatic global growth, blending a focus on both commercial and study operations, while building out an international team to support Clinical Ink’s customers.

“Clinical Ink is hyper-focused on delivering results for our customers,” said Clinical Ink CEO Ed Seguine. “While our primary competitors are focused on concocting their next stage of funding, Clinical Ink is hiring the best people in the industry to better deliver for our customers. As a profitable, mature company and undisputed eSource leader, we are building out our global customer support infrastructure to ensure our explosive growth does not outstrip our ability to provide unparalleled customer service. Janette brings tremendous expertise to our executive team and is the right person to build out our international operations.”

“I believe Clinical Ink’s technology platform and service-first approach will solve the industry’s biggest problems now and into the future,” said Janette. “I’m excited to ensure our customers have solutions to the dynamic clinical and operational challenges that have afflicted this industry for so long. Joining Clinical Ink is an expression of my optimism about the future and I look forward to collaborating and partnering with our customers to confidently address the great potential for technology to improve the clinical trial experience for patients and sites.”

Prior to joining Clinical Ink, Janette was at Medidata Solutions for 13 years in a variety of roles, and worked for a number of eCOA technology providers in the earlier part of her career. Most recently, she was Vice President, Global Partner Initiatives & Partner Business Management, where she was responsible for the global leadership and management of Medidata’s Partner Study-by-Study Business. Working with CRO partners on a global scale from proposal through to contract execution, Janette was instrumental in the transformation of strategy, processes, and GTM approach to address the needs of the most demanding pharma and biotech customers.

Clinical Ink’s Lunexis platform collects clinical trial data from patients and clinicians, at home and on-site. In the past three years, project bookings have tripled, revenue more than quadrupled, and backlog has grown by 500%. Clinical Ink has conducted hundreds of clinical trials on the Lunexis decentralized trial platform, capturing data from patients where they live — everywhere from villages in West Africa, mountaintops in Nepal, nursing homes in Europe, and patient homes in 60+ countries. Lunexis began as a way to transition sites from EDC to DDC (eSource) and to enable easier patient participation at home with BYOD ePRO+. It now offers Build Your Own Study capabilities for sponsors and CROs to have greater control over study design and execution.

About Clinical Ink
Clinical Ink, a global clinical technology company, offers data certainty from source to submission via our Lunexis eSource clinical technology and configurable direct data capture, eCOA, ePRO, and eConsent modules. This suite of solutions for capturing and integrating electronic data from sites, clinicians, and patients at its source naturally enhances clinical trial workflows. For virtual, traditional, or hybrid trials, Lunexis technology reduces manual labor and provides anytime, anywhere data access, saving resources as your trials progress.

The post Clinical Ink Hires Industry Veteran Janette Morgan as General Manager, EMEA appeared first on Clinical ink.

HORSHAM, Pa.; May 4, 2021 – Clinical Ink, a global clinical trial technology company, today announced the hiring of CCO Chris Crucitti, COO Brian Donahue, and VP Project Operations Bill Barrasso. All three positions are newly created to help manage the unprecedented industry demand for the eSource leader’s eCOA, ePRO+, DDC, and eConsent platform.

“Clinical Ink pioneered the development of decentralized trials (eSource) long before the label even existed and we are responding to the tremendous growth opportunities ahead,” said Clinical Ink CEO, Ed Seguine. “This industry is plagued with visionary talk that so often lacks substance and comes up short in real-life. Adding these experienced industry veterans builds on the disciplined execution mindset we have cultivated over the years. These leaders bring great insight, expertise, and vision to our confident, reliable delivery of results in the most complex and demanding therapeutic areas.”

Clinical Ink’s Lunexis platform collects clinical trial data from patients and clinicians, at home and on-site. In the past three years, project bookings have tripled, revenue more than quadrupled, and backlog has grown by 500%. Clinical Ink has conducted hundreds of clinical trials on the Lunexis decentralized trial platform, capturing data from patients where they live — everywhere from villages in West Africa, mountaintops in Nepal, nursing homes in Europe, and patient homes in 60+ countries. Lunexis began as a way to transition sites from EDC to DDC (eSource) and to enable easier patient participation at home with BYOD ePRO+. It now offers “Build Your Own Study” capabilities for sponsors and CROs to have greater control over study design and execution.

Chris Crucitti, Chief Commercial Officer
Christopher L. Crucitti is a 20+ year life sciences and clinical services/technology executive. Prior to joining Clinical Ink, Chris most recently held the role of Chief Commercial Officer at Signant Health, where he led the commercial functions and go-to-market strategy. In addition, Chris brings significant experience and expertise in the clinical and R&D domains, including full-service CRO, data and analytics, eClinical technology solutions, strategic resourcing, and consulting.

“I am very excited to join Clinical Ink’s team of incredibly smart, passionate, and committed problem-solvers,” said Crucitti. “My primary goals are to solidify Clinical Ink’s customer-focused approach as we continue our rapid growth, to optimize an already high performing go-to-market strategy, and to build a trusted expertise-based partnership model with our customers. We will also continue to innovate, while demonstrating thought-leadership, to meet the critical goals and challenges of our customers in a quickly evolving clinical development landscape. Clinical Ink has quietly been involved in some of the most consequential clinical programs over the past several years and I look forward to the many opportunities to expedite the process of delivering meaningful treatments to the patients who need them.”

Brian Donahue, Chief Operating Officer
Prior to joining Clinical Ink, Brian held a variety of leadership roles at GE for 16 years. Brian started his career in GE’s world-renowned Operations Leadership Program. This led to multiple roles within GE Capital prior to his transition to GE Healthcare, where he served in multiple operational, commercial, and general management leadership positions in the U.S. and Canada.

“Leading Clinical Ink through its next phase of growth will require expanded operations functions with an emphasis on superior customer support across the organization,” said Donahue. “The ongoing support of our customer base and enhanced data reporting will be integral to customer satisfaction and retention, and I look forward to developing our strategy for shared services, project management, and operations functions across the business.”

Bill Barrasso, Vice President, Project Operations
Bill Barrasso brings a deep understanding of clinical trial processes and regulatory guidance required for successful study execution. Bill established the eCOA delivery services team at Parexel after leading eCOA services organizations at both ERT and PHT Corporation. Prior to that, he was the Director of Operations at Concordant Rater Systems (rater monitoring and eCOA data collection in CNS studies), which was acquired by United BioSource Corporation and spun off into Bracket.

“Global delivery processes, excellence in execution, and operational strategies for the delivery services organization will ensure Clinical Ink remains at the forefront of the eCOA/eSource/ Decentralized Trial transformation,” said Barrasso. “I look forward to driving study management processes that deliver high-quality and timely solutions to our valued clients.”

About Clinical Ink
Clinical Ink, a global clinical technology company, offers data certainty from source to submission via our Lunexis eSource clinical technology and configurable direct data capture, eCOA, ePRO+, and eConsent modules. This suite of solutions for capturing and integrating electronic data from sites, clinicians, patients, and caregivers at its source naturally enhances clinical trial workflows. For virtual, traditional, or hybrid trials, Lunexis technology reduces manual labor and associated delays, and provides anytime, anywhere data access, saving resources as your trials progress. For more information, visit Clinical Ink.

The post Clinical Ink Hires CCO Chris Crucitti, COO Brian Donahue, VP Bill Barrasso appeared first on Clinical ink.

“After 20+ years of involvement with DIA, this moment only reignites my passion for changing the future of global health,” said Andrus. “It truly marks a renewed desire to continue to revolutionize clinical research with Clinical Ink’s future-built platforms and vision of eliminating paper source documents in clinical research.”

Like DIA’s mission to foster innovation and improve health and well-being worldwide, Clinical Ink is committed to dramatically reducing the cost and complexity of clinical research for sites, sponsors, and patients. Its pioneering EDC replacement, eCOA, and ePRO solutions are designed to support paperless clinical trials and make capturing, validating, and sharing data electronically both cleaner and faster, which ultimately helps accelerate new treatments to patients who need them.

Clinical Ink has completed over 200 studies — with experience in phase I, II, and III studies. Visit Andrus and the rest of the Clinical Ink team in Booth 2537 at DIA’s global, annual meeting to learn more about their EDC replacement, eCOA, and ePRO solutions.

Andrus will be delivering two presentations on Tuesday, June 25, at DIA’s global, annual meeting in San Diego, CA. At 2 p.m., he will join FDA and MHRA speakers to discuss: Electronic Systems: Are Yours Fit for Purpose? His 4:15 p.m. presentation is titled: Real World Evidence: How Does it Use Challenge Quality and Compliance Programs?  In this presentation, he will be joined by speakers from the FDA and the MHRA.

About Clinical Ink

Clinical Ink is a global clinical trial technology company that is transforming the clinical trial experience. Founded in 2007, the company’s proven and future-built eSource platform, which includes solutions for EDC replacement, eCOA, ePRO, and more, accelerates time to value while delivering scientific results that matter. With offices in Winston-Salem, NC, and Philadelphia, PA, Clinical Ink is advancing the business model responsible for bringing new treatments to market.

CONTACT:
Jane Byram
SCORR Marketing
512.626.2758
jane@scorrmarketing.com

The post Clinical Ink’s Jonathan R. Andrus Receives 2019 Inspire Award From DIA appeared first on Clinical ink.

Passionate about data management, Jonathan has helped grow the professional society on a global scale, including playing a major role in moving its headquarters from the US to Europe. Further, he has been instrumental in working with the society’s European, Indian, Chinese and Japanese members, supporting and growing activities in these regions with the aim of globally advancing data management.

At Clinical Ink, Jonathan focuses his initiatives on providing customers with the most compliant, efficient and quality-oriented products and services, stating, “Customer satisfaction is my number one priority and our entire company is united under the mission of providing our customers with the best possible experience by delivering a modern approach to clinical trial execution and data management.”

Congratulations to Jonathan for this tremendous recognition. Clinical Ink and the clinical trial data management industry are appreciative of your contributions to advancing clinical trial execution.

About Clinical Ink

Clinical Ink is a global clinical trial technology company that is transforming the clinical trial experience. Founded in 2007, the Company’s proven and future-built CAPTURE platform, which includes solutions for EDC replacement, eCOA, ePRO and more, accelerates time to value while delivering scientific results that matter. With offices in Winston-Salem, NC, and Philadelphia, PA, Clinical Ink is advancing the business model responsible for bringing new treatments to market. Visit clinicalink.com.

Media Contact: Jessica Romero | 336.728.6541 | jessica.romero@clinicalink.com

The post Clinical Ink’s COO & Chief Data Officer, Jonathan Andrus, Awarded SCDM Lifetime Achievement Award appeared first on Clinical ink.